brand logo

Am Fam Physician. 2021;103(12):760-761

This clinical content conforms to AAFP criteria for CME.

Author disclosure: No relevant financial affiliations.

Clinical Question

In patients reporting a penicillin allergy, is it possible to determine the likelihood of true allergy without formal testing?

Evidence Summary

Penicillin allergy is the most commonly documented drug allergy in medical records, with a prevalence of approximately 10% of all patients.1 However, in up to 90% of patients with a reported allergy, penicillins are tolerated on allergy testing.2 As a consequence of patients being labeled as having a penicillin allergy, alternative (typically broader-spectrum) antibiotic classes are often used, with potentially poorer efficacy and safety profiles. This leads to increased multidrug-resistant organisms, treatment failure, and health care costs and prolonged hospitalizations.3

A formal drug challenge is the preferred test for investigating immunoglobulin E–mediated penicillin hypersensitivity (type I hypersensitivity)4; skin testing is also a commonly used validated tool.1 A number of studies have been performed to develop clinical prediction rules using features of the allergy history to help determine which patients labeled as having a penicillin allergy can safely be given a beta-lactam antibiotic. Despite the high prevalence of patients labeled as having a penicillin allergy, there is an international shortage of those proficient in conducting formal drug challenges.5

A study in a tertiary referral center in the United Kingdom used multivariable logistic regression to identify patients at low risk of type I beta-lactam allergy.6 This included patients who had no history of anaphylaxis, who had a reaction more than one year before referral, and who could not recall what the index drug was. Only 1.6% of patients with all of these traits had type I hypersensitivity. Another study derived and validated two algorithms in a retrospective cohort of individuals evaluated for beta-lactam allergy.7 Similarly, anaphylaxis, shorter time since the reaction occurred, and reaction onset less than one hour after most recent drug intake were identified as predictors of a true allergy. However, both algorithms had low sensitivity (51% and 60%), precluding their clinical use.7

A more recent study derived and validated a clinical prediction rule for penicillin allergy.8 The PEN-FAST (penicillin allergy, five or fewer years ago, anaphylaxis/angioedema, severe, treatment) rule was derived from a prospective cohort of 622 allergy-tested patients in Melbourne, Australia, using a multivariable logistic regression model. This identified five independent predictors of an oral challenge positive for penicillin allergy. Discrimination (the ability to separate those with a positive allergy result from those without) was shown to be good in the derivation and internal validation cohort (area under the curve = 0.81). Calibration (agreement between predicted and observed rates of allergy) was also good across multiple measures.

External validation was performed in multi-center retrospective cohorts in Australia (Perth, n = 334; Sydney, n = 80) and the United States (Nashville, Tenn., n = 531), with 94% of participants undergoing an oral penicillin challenge and the remainder undergoing a scratch test or intradermal test alone.8

The study identified three risk factors to include in the clinical prediction rule8:

  • Allergy event occurring five or fewer years ago (2 points)

  • Anaphylaxis/angioedema or severe cutaneous adverse reaction (2 points)

  • Treatment required for the episode (1 point)

Total scoring ranged from 0 to 5, allowing for stratification of patients based on risk of a positive result on penicillin allergy testing8:

  • Very low (0 points): 0.6% risk (1 out of 164)

  • Low (1 or 2 points): 5% risk (16 out of 296)

  • Moderate (3 points): 19% risk (25 out of 132)

  • High (4 or 5 points): 53% risk (16 out of 30)

The investigators chose a cutoff score of less than 3 points, which yielded a sensitivity of 70.7% (95% CI, 57.3% to 81.9%) and specificity of 78.5% (95% CI, 74.9% to 81.9%) in the derivation cohort. A total of 74% of the cohort had a score of less than 3, and, of these patients, only 3.7% (17 out of 460) had a positive test result.8 However, different cutoff scores may be considered for risk stratification depending on clinician preference, the setting, and capacity for allergy testing.

Already a member/subscriber?  Log In

Subscribe

From $145
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available

Article Only

$25.95
  • Immediate, unlimited access to just this article
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

Continue Reading

More in AFP

More in Pubmed

Copyright © 2021 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.